Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
370-07-053 ISMRM Abstract

Identifying Chemotherapy-Sensitive Nasopharyngeal Carcinoma Patients Using Biomechanical Parameters

Primary: Body - Whole Body Imaging
Secondary: Transferable Skills
370-07-053 · Quantitative Imaging · Monday, 11 May, 2:45 PM–3:40 PM · Traditional Posters | Exhibition Hall
Keywords: Treatment Response Nasopharyngeal carcinoma MRE
Accepted
Huanhuan Ren 1, Yao Huang2, Qian Xu2, Daihong Liu3, Yulin Wang4, Junhao Huang5, Xinying Ren5, Ting Yin6, Jiuquan Zhang3
1Department of Radiology Chongqing University Cancer Hospital, Chongqing, chongqing, China
2School of Medicine, Chongqing University, China
3Department of Radiology, Chongqing University Cancer Hospital, Chongqing, China
4School of Medicine, School of Medicine, Chongqing University, China
5Department of Radiology, Chongqing University Cancer Hospital, Chongqing, China
6MR Collaborations, Siemens Healthineers Ltd.Chengdu, China
Presenting Author: Huanhuan Ren

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Tang LL, Chen YP, Chen CB, et al. The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma. Cancer Commun (Lond) 2021;41:1195-1227
2. Zhang Y, Chen L, Hu GQ, et al. Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial. J Clin Oncol 2022;40:2420–2425
3. Han B, Zhang H, Tian R, et al. Exosomal EPHA2 derived from highly metastatic breast cancer cells promotes angiogenesis by activating the AMPK signaling pathway through Ephrin A1-EPHA2 forward signaling. Theranostics. 2022;12(9):4127–4146.
4. Zhou IY, Clavijo Jordan V, Rotile NJ, et al. Advanced MRI of Liver Fibrosis and Treatment Response in a Rat Model of Nonalcoholic Steatohepatitis. Radiology. 2020;296(1):67–75.
5. Cao Y, Ge X, Zhu X, et al. Transformable Neuropeptide Prodrug with Tumor Microenvironment Responsiveness for Tumor Growth and Metastasis Inhibition of Triple-Negative Breast Cancer. Adv Sci (Weinh). 2023;10(21):e2300545.
6. Liao H, Zhao, Y., Pei, W., et al. An interpretable machine learning model assists in predicting induction chemotherapy response and survival for locoregionally advanced nasopharyngeal carcinoma using MRI: a multicenter study. European radiology, 2025;35(8), 5121–5134.
7. Zhao, L., Gong, J., Xi, Y., et al. MRI-based radiomics nomogram may predict the response to induction chemotherapy and survival in locally advanced nasopharyngeal carcinoma. European radiology, 2020;30(1), 537–546.
8. Yao, J., Wang, Y., Lin, Y., et al. The Role of Pretreatment 18F-FDG PET/CT for Early Prediction of Neoadjuvant Chemotherapy Response in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma. Drug design, development and therapy, 2021;15, 4157–4166.
9. Shi, Z., Huang, X., Cheng, Z., et al. MRI-based Quantification of Intratumoral Heterogeneity for Predicting Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer. Radiology, 2023;308(1), e222830.
10. Huang, Y., Song, X., Chen, Y., et al. Intratumoral Microbiome-related MRI Model for Predicting Breast Cancer Shrinkage Pattern Following Neoadjuvant Therapy. Radiology, 2025;316(2), e243545.

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/370-07-053